https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51134 Wed 28 Feb 2024 16:20:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50124 Wed 28 Feb 2024 16:17:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51393 Wed 28 Feb 2024 16:04:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53765 Wed 28 Feb 2024 15:59:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50606 Wed 28 Feb 2024 15:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54297 Wed 28 Feb 2024 15:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50469 Wed 28 Feb 2024 15:49:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52688 Wed 28 Feb 2024 15:49:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54338 Wed 28 Feb 2024 15:14:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50453 Wed 28 Feb 2024 15:13:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51503 Wed 28 Feb 2024 14:50:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51924 Wed 28 Feb 2024 09:57:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40357 Wed 27 Jul 2022 15:15:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43527 Wed 21 Sep 2022 11:32:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51839 Wed 20 Sep 2023 16:12:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52293 Wed 17 Apr 2024 14:31:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44505 Wed 16 Aug 2023 09:41:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47060 Wed 13 Mar 2024 08:04:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43927 n = 157) and without (n = 79) asthma. Mothers with asthma participated in this study following participation in a randomized controlled trial of a novel asthma management strategy during pregnancy. Mothers completed the Parenting Stress Index Short Form during the first 12 months postpartum. Mothers with asthma also completed the Asthma Control Questionnaire. Results: Parenting stress did not differ between mothers with and without asthma. Additionally, for mothers with asthma, there were no differences in levels of parenting stress based on asthma control. Conclusions: This study suggests that mothers with asthma are not at an increased risk for excessive parenting stress. However, due to response and sampling bias, levels of parenting stress in asthmatic mothers may be underreported in our sample.]]> Wed 13 Mar 2024 08:01:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52410 Wed 11 Oct 2023 11:59:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53688 Wed 10 Jan 2024 10:34:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50859 Wed 09 Aug 2023 10:13:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50855 Wed 09 Aug 2023 09:52:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52619 Wed 06 Mar 2024 15:31:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48046 Wed 06 Mar 2024 15:13:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54622 Wed 06 Mar 2024 10:53:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54624 Wed 06 Mar 2024 10:53:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54623 Wed 06 Mar 2024 10:51:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52146 Wed 04 Oct 2023 10:20:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50541 Wed 02 Aug 2023 13:55:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52880 Tue 31 Oct 2023 10:44:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49760 Tue 30 May 2023 18:39:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54427 Tue 27 Feb 2024 13:53:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39820 Tue 26 Jul 2022 11:33:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46337 P = .01), emergency visit (RR = 8.61, P = .03), and hospitalization (RR = 12.94, P < .01). Results of the cluster analysis were successfully validated in an independent PGA population classified using decision tree analysis. Although PGA can transform into or develop from other phenotypes, 70% were stable over time. Conclusions: Among 3 identified PGA clusters, cluster 3 had a higher risk of severe exacerbation. PGA heterogeneity indicates the requirement of novel targeted interventions.]]> Tue 15 Nov 2022 15:03:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52770 Tue 14 Nov 2023 15:04:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46987 Tue 13 Dec 2022 09:28:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53621 Tue 12 Dec 2023 15:19:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52374 Tue 10 Oct 2023 14:37:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45548 Tue 01 Nov 2022 11:07:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40658 Thu 28 Jul 2022 12:42:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39670 Thu 28 Jul 2022 08:10:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45347 Thu 27 Oct 2022 17:08:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45375 Thu 27 Oct 2022 16:54:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46415 Thu 24 Nov 2022 13:56:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51880 Thu 21 Sep 2023 10:25:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54912 Thu 21 Mar 2024 12:03:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48433 Thu 16 Mar 2023 14:17:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54288 Thu 15 Feb 2024 14:47:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48870 Thu 13 Apr 2023 12:48:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50895 Thu 10 Aug 2023 10:29:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40293 Thu 07 Jul 2022 15:11:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49083 Thu 04 May 2023 09:25:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46830 Thu 01 Dec 2022 11:45:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54592 Sat 02 Mar 2024 11:19:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52861 100, one contributing to meta‐analysis), mean age range 27 to 54 years). We identified one ongoing study and three studies awaiting classification. One study was synthesised narratively, and another involved participants specifically with asthma‐COPD overlap. Most programmes were outpatient‐based, lasting from three to four weeks (inpatient) or eight to 12 weeks (outpatient). Education or self‐management components included breathing retraining and relaxation, nutritional advice and psychological counselling. One programme was specifically tailored for people with severe asthma. Pulmonary rehabilitation compared to usual care may increase maximal oxygen uptake (VO2 max) after programme completion, but the evidence is very uncertain for data derived using mL/kg/min (MD between groups of 3.63 mL/kg/min, 95% confidence interval (CI) 1.48 to 5.77; 3 studies; n = 129) and uncertain for data derived from % predicted VO2 max (MD 14.88%, 95% CI 9.66 to 20.1%; 2 studies; n = 60). The evidence is very uncertain about the effects of pulmonary rehabilitation compared to usual care on incremental shuttle walk test distance (MD between groups 74.0 metres, 95% CI 26.4 to 121.4; 1 study; n = 30). Pulmonary rehabilitation may have little to no effect on VO2 max at longer‐term follow up (9 to 12 months), but the evidence is very uncertain (MD −0.69 mL/kg/min, 95% CI −4.79 to 3.42; I2 = 49%; 3 studies; n = 66). Pulmonary rehabilitation likely improves functional exercise capacity as measured by 6‐minute walk distance, with MD between groups after programme completion of 79.8 metres (95% CI 66.5 to 93.1; 5 studies; n = 529; moderate certainty evidence). This magnitude of mean change exceeds the minimally clinically important difference (MCID) threshold for people with chronic respiratory disease. The evidence is very uncertain about the longer‐term effects one year after pulmonary rehabilitation for this outcome (MD 52.29 metres, 95% CI 0.7 to 103.88; 2 studies; n = 42). Pulmonary rehabilitation may result in a small improvement in asthma control compared to usual care as measured by Asthma Control Questionnaire (ACQ), with an MD between groups of −0.46 (95% CI −0.76 to −0.17; 2 studies; n = 93; low certainty evidence); however, data derived from the Asthma Control Test were very uncertain (MD between groups 3.34, 95% CI −2.32 to 9.01; 2 studies; n = 442). The ACQ finding approximates the MCID of 0.5 points. Pulmonary rehabilitation results in little to no difference in asthma control as measured by ACQ at nine to 12 months follow‐up (MD 0.09, 95% CI −0.35 to 0.53; 2 studies; n = 48; low certainty evidence). Pulmonary rehabilitation likely results in a large improvement in quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ) total score (MD −18.51, 95% CI −20.77 to −16.25; 2 studies; n = 440; moderate certainty evidence), with this magnitude of change exceeding the MCID. However, pulmonary rehabilitation may have little to no effect on Asthma Quality of Life Questionnaire (AQLQ) total scores, with the evidence being very uncertain (MD 0.87, 95% CI −0.13 to 1.86; 2 studies; n = 442). Longer‐term follow‐up data suggested improvements in quality of life may occur as measured by SGRQ (MD −13.4, 95% CI −15.93 to −10.88; 2 studies; n = 430) but not AQLQ (MD 0.58, 95% CI −0.23 to 1.38; 2 studies; n = 435); however, the evidence is very uncertain. One study reported no difference between groups in the proportion of participants who experienced an asthma exacerbation during the intervention period. Data from one study suggest adverse events attributable to the intervention are rare. Overall risk of bias was most commonly impacted by performance bias attributed to a lack of participant blinding to knowledge of the intervention. This is inherently challenging to overcome in rehabilitation studies. Authors' conclusions: Moderate certainty evidence shows that pulmonary rehabilitation is probably associated with clinically meaningful improvements in functional exercise capacity and quality of life upon programme completion in adults with asthma. The certainty of evidence relating to maximal exercise capacity was very low to low. Pulmonary rehabilitation appears to confer minimal effect on asthma control, although the certainty of evidence is very low to low. Unclear reporting of study methods and small sample sizes limits our certainty in the overall body of evidence, whilst heterogenous study designs and interventions likely contribute to inconsistent findings across clinical outcomes and studies. There remains considerable scope for future research.]]> Mon 30 Oct 2023 10:01:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54966 Mon 25 Mar 2024 12:11:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44823 Mon 24 Oct 2022 09:45:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44806 Mon 24 Oct 2022 09:31:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53946 Mon 22 Jan 2024 16:57:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53947 Mon 22 Jan 2024 16:56:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50309 Mon 17 Jul 2023 15:17:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47390 Mon 16 Jan 2023 15:52:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46274 Mon 14 Nov 2022 15:28:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46232 Mon 14 Nov 2022 12:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46219 Mon 14 Nov 2022 12:04:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46221 Mon 14 Nov 2022 12:04:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50981 Mon 14 Aug 2023 15:39:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52317 Mon 09 Oct 2023 10:23:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40279 Mon 08 Aug 2022 11:55:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55058 Mon 08 Apr 2024 09:43:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53538 Mon 04 Dec 2023 15:44:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52803 Fri 27 Oct 2023 14:06:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51945 Fri 22 Sep 2023 16:57:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51908 50%. Computed tomography of the larynx is a new technology with potential for swift diagnosis that requires validation in clinical pathways. Disease pathogenesis and multimorbidity interactions are complex reflecting a multi-factorial, complex condition, with no single overarching disease mechanism. Currently there is no evidence-based standard of care since randomized trials for treatment are non-existent. Recent multidisciplinary models of care need to be clearly articulated and prospectively investigated. Patient impact and healthcare utilization can be formidable but have largely escaped inquiry and patient perspectives have not been explored. Roundtable participants expressed optimism as collective understanding of this complex condition evolves. The Melbourne VCD/ILO Roundtable 2022 identified clear priorities and future directions for this impactful condition.]]> Fri 22 Sep 2023 10:25:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52690 Fri 20 Oct 2023 11:29:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52669 Fri 20 Oct 2023 09:24:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52668 Fri 20 Oct 2023 09:24:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46329 Fri 18 Nov 2022 09:59:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53104 Fri 17 Nov 2023 11:38:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47321 Fri 13 Jan 2023 11:06:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47306 Fri 13 Jan 2023 10:52:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49414 Fri 12 May 2023 15:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46081 adj], 18.10 and 19.17, respectively) and mechanical ventilation (RR_adj , 2.56 and 5.71, respectively) than did cluster 1. Individuals in cluster 3 had an extended length of hospital stay (11 days), increased hospitalization direct costs (13,481.57 Chinese Yuan), and a higher risk of ICU admission (RR_adj , 2.14) than individuals in clusters 1 and 2. The decision tree assigned 90.8% of the participants correctly. Conclusions: We identified 3 phenotypes with differential clinical and inflammatory characteristics associated with in-hospital adverse outcomes. These new phenotypes might have important and clinically relevant implications for the management of patients hospitalized for AEs.]]> Fri 11 Nov 2022 15:15:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51239 Fri 10 Nov 2023 07:15:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54653 Fri 08 Mar 2024 09:54:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40363 Fri 08 Jul 2022 14:24:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50204 Fri 07 Jul 2023 10:17:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49200 Fri 05 May 2023 15:58:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55056 Fri 05 Apr 2024 14:28:53 AEDT ]]>